Summary

Drug and Gene Delivery Systems Market – Scope of Report
TMR’s report on the global drug and gene delivery systems market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global drug and gene delivery systems market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global drug and gene delivery systems market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the drug and gene delivery systems market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global drug and gene delivery systems market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global drug and gene delivery systems market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global drug and gene delivery systems market.

The report delves into the competitive landscape of the global drug and gene delivery systems market. Key players operating in the global drug and gene delivery systems market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global drug and gene delivery systems market profiled in this report.

Key Questions Answered in Global drug and gene delivery systems Market Report
• What is the sales/revenue generated by drug and gene delivery systems across all regions during the forecast period?
• What are the opportunities in the global drug and gene delivery systems market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Drug and Gene Delivery Systems Market – Research Objectives and Research Approach
The comprehensive report on the global drug and gene delivery systems market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global drug and gene delivery systems market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global drug and gene delivery systems market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Drug and Gene Delivery Systems Market
4. Market Overview
4.1. Introduction
4.1.1. Delivery System Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Drug and Gene Delivery Systems Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Delivery System/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Delivery System
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Delivery System, 2017–2031
6.3.1. Drug Delivery Systems
6.3.1.1. Intrauterine Implants
6.3.1.2. Prodrug Implants
6.3.1.3. Polymeric Drug Delivery
6.3.1.4. Targeted Drug Delivery
6.3.2. Gene Delivery Systems
6.3.2.1. Viral Gene Delivery
6.3.2.1.1. Adenovirus Vector
6.3.2.1.2. Lentivirus Vector
6.3.2.1.3. Retrovirus Vector
6.3.2.1.4. Adeno-associated Virus Vector
6.3.2.1.5. Sendai Virus Vector
6.3.2.1.6. Herpes Simplex Virus Vector
6.3.2.1.7. Others
6.3.2.2. Non-viral Gene Delivery
6.3.2.2.1. Natural Organic Compounds
6.3.2.2.2. Physical Methods
6.3.2.2.3. Chemical Methods
6.3.2.3. Combined Hybrid System
6.4. Market Attractiveness Analysis, by Delivery System
7. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Route of Administration
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Route of Administration, 2017–2031
7.3.1. Oral
7.3.2. Injectable
7.3.3. Inhalation
7.3.4. Transdermal
7.3.5. Ocular
7.3.6. Nasal
7.3.7. Topical
7.4. Market Attractiveness Analysis, by Route of Administration
8. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Application
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Application, 2017–2031
8.3.1. Infectious Diseases
8.3.2. Oncology
8.3.3. Ophthalmology
8.3.4. Urology
8.3.5. Diabetes
8.3.6. CNS
8.3.7. Others
8.4. Market Attractiveness Analysis, by Application
9. Global Drug and Gene Delivery Systems Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Drug and Gene Delivery Systems Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Delivery System, 2017–2031
10.3.1. Drug Delivery Systems
10.3.1.1. Intrauterine Implants
10.3.1.2. Prodrug Implants
10.3.1.3. Polymeric Drug Delivery
10.3.1.4. Targeted Drug Delivery
10.3.2. Gene Delivery Systems
10.3.2.1. Viral Gene Delivery
10.3.2.1.1. Adenovirus Vector
10.3.2.1.2. Lentivirus Vector
10.3.2.1.3. Retrovirus Vector
10.3.2.1.4. Adeno-associated Virus Vector
10.3.2.1.5. Sendai Virus Vector
10.3.2.1.6. Herpes Simplex Virus Vector
10.3.2.1.7. Others
10.3.2.2. Non-viral Gene Delivery
10.3.2.2.1. Natural Organic Compounds
10.3.2.2.2. Physical Methods
10.3.2.2.3. Chemical Methods
10.3.2.3. Combined Hybrid System
10.4. Market Value Forecast, by Route of Administration, 2017–2031
10.4.1. Oral
10.4.2. Injectable
10.4.3. Inhalation
10.4.4. Transdermal
10.4.5. Ocular
10.4.6. Nasal
10.4.7. Topical
10.5. Market Value Forecast, by Application, 2017–2031
10.5.1. Infectious Diseases
10.5.2. Oncology
10.5.3. Ophthalmology
10.5.4. Urology
10.5.5. Diabetes
10.5.6. CNS
10.5.7. Others
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Delivery System
10.7.2. By Route of Administration
10.7.3. By Application
10.7.4. By Country
11. Europe Drug and Gene Delivery Systems Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Delivery System, 2017–2031
11.3.1. Drug Delivery Systems
11.3.1.1. Intrauterine Implants
11.3.1.2. Prodrug Implants
11.3.1.3. Polymeric Drug Delivery
11.3.1.4. Targeted Drug Delivery
11.3.2. Gene Delivery Systems
11.3.2.1. Viral Gene Delivery
11.3.2.1.1. Adenovirus Vector
11.3.2.1.2. Lentivirus Vector
11.3.2.1.3. Retrovirus Vector
11.3.2.1.4. Adeno-associated Virus Vector
11.3.2.1.5. Sendai Virus Vector
11.3.2.1.6. Herpes Simplex Virus Vector
11.3.2.1.7. Others
11.3.2.2. Non-viral Gene Delivery
11.3.2.2.1. Natural Organic Compounds
11.3.2.2.2. Physical Methods
11.3.2.2.3. Chemical Methods
11.3.2.3. Combined Hybrid System
11.4. Market Value Forecast, by Route of Administration, 2017–2031
11.4.1. Oral
11.4.2. Injectable
11.4.3. Inhalation
11.4.4. Transdermal
11.4.5. Ocular
11.4.6. Nasal
11.4.7. Topical
11.5. Market Value Forecast, by Application, 2017–2031
11.5.1. Infectious Diseases
11.5.2. Oncology
11.5.3. Ophthalmology
11.5.4. Urology
11.5.5. Diabetes
11.5.6. CNS
11.5.7. Others
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Delivery System
11.7.2. By Route of Administration
11.7.3. By Application
11.7.4. By Country/Sub-region
12. Asia Pacific Drug and Gene Delivery Systems Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Delivery System, 2017–2031
12.3.1. Drug Delivery Systems
12.3.1.1. Intrauterine Implants
12.3.1.2. Prodrug Implants
12.3.1.3. Polymeric Drug Delivery
12.3.1.4. Targeted Drug Delivery
12.3.2. Gene Delivery Systems
12.3.2.1. Viral Gene Delivery
12.3.2.1.1. Adenovirus Vector
12.3.2.1.2. Lentivirus Vector
12.3.2.1.3. Retrovirus Vector
12.3.2.1.4. Adeno-associated Virus Vector
12.3.2.1.5. Sendai Virus Vector
12.3.2.1.6. Herpes Simplex Virus Vector
12.3.2.1.7. Others
12.3.2.2. Non-viral Gene Delivery
12.3.2.2.1. Natural Organic Compounds
12.3.2.2.2. Physical Methods
12.3.2.2.3. Chemical Methods
12.3.2.3. Combined Hybrid System
12.4. Market Value Forecast, by Route of Administration, 2017–2031
12.4.1. Oral
12.4.2. Injectable
12.4.3. Inhalation
12.4.4. Transdermal
12.4.5. Ocular
12.4.6. Nasal
12.4.7. Topical
12.5. Market Value Forecast, by Application, 2017–2031
12.5.1. Infectious Diseases
12.5.2. Oncology
12.5.3. Ophthalmology
12.5.4. Urology
12.5.5. Diabetes
12.5.6. CNS
12.5.7. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Delivery System
12.7.2. By Route of Administration
12.7.3. By Application
12.7.4. By Country/Sub-region
13. Latin America Drug and Gene Delivery Systems Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Delivery System, 2017–2031
13.3.1. Drug Delivery Systems
13.3.1.1. Intrauterine Implants
13.3.1.2. Prodrug Implants
13.3.1.3. Polymeric Drug Delivery
13.3.1.4. Targeted Drug Delivery
13.3.2. Gene Delivery Systems
13.3.2.1. Viral Gene Delivery
13.3.2.1.1. Adenovirus Vector
13.3.2.1.2. Lentivirus Vector
13.3.2.1.3. Retrovirus Vector
13.3.2.1.4. Adeno-associated Virus Vector
13.3.2.1.5. Sendai Virus Vector
13.3.2.1.6. Herpes Simplex Virus Vector
13.3.2.1.7. Others
13.3.2.2. Non-viral Gene Delivery
13.3.2.2.1. Natural Organic Compounds
13.3.2.2.2. Physical Methods
13.3.2.2.3. Chemical Methods
13.3.2.3. Combined Hybrid System
13.4. Market Value Forecast, by Route of Administration, 2017–2031
13.4.1. Oral
13.4.2. Injectable
13.4.3. Inhalation
13.4.4. Transdermal
13.4.5. Ocular
13.4.6. Nasal
13.4.7. Topical
13.5. Market Value Forecast, by Application, 2017–2031
13.5.1. Infectious Diseases
13.5.2. Oncology
13.5.3. Ophthalmology
13.5.4. Urology
13.5.5. Diabetes
13.5.6. CNS
13.5.7. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Delivery System
13.7.2. By Route of Administration
13.7.3. By Application
13.7.4. By Country/Sub-region
14. Middle East & Africa Drug and Gene Delivery Systems Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Delivery System, 2017–2031
14.3.1. Drug Delivery Systems
14.3.1.1. Intrauterine Implants
14.3.1.2. Prodrug Implants
14.3.1.3. Polymeric Drug Delivery
14.3.1.4. Targeted Drug Delivery
14.3.2. Gene Delivery Systems
14.3.2.1. Viral Gene Delivery
14.3.2.1.1. Adenovirus Vector
14.3.2.1.2. Lentivirus Vector
14.3.2.1.3. Retrovirus Vector
14.3.2.1.4. Adeno-associated Virus Vector
14.3.2.1.5. Sendai Virus Vector
14.3.2.1.6. Herpes Simplex Virus Vector
14.3.2.1.7. Others
14.3.2.2. Non-viral Gene Delivery
14.3.2.2.1. Natural Organic Compounds
14.3.2.2.2. Physical Methods
14.3.2.2.3. Chemical Methods
14.3.2.3. Combined Hybrid System
14.4. Market Value Forecast, by Route of Administration, 2017–2031
14.4.1. Oral
14.4.2. Injectable
14.4.3. Inhalation
14.4.4. Transdermal
14.4.5. Ocular
14.4.6. Nasal
14.4.7. Topical
14.5. Market Value Forecast, by Application, 2017–2031
14.5.1. Infectious Diseases
14.5.2. Oncology
14.5.3. Ophthalmology
14.5.4. Urology
14.5.5. Diabetes
14.5.6. CNS
14.5.7. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Delivery System
14.7.2. By Route of Administration
14.7.3. By Application
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Novartis AG
15.3.1.1. Company Overview
15.3.1.2. Delivery System Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. Amgen Inc.
15.3.2.1. Company Overview
15.3.2.2. Delivery System Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Oxford BioMedica plc.
15.3.3.1. Company Overview
15.3.3.2. Delivery System Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. SIBIONO
15.3.4.1. Company Overview
15.3.4.2. Delivery System Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Shanghai Sunway Biotech Co., Ltd.
15.3.5.1. Company Overview
15.3.5.2. Delivery System Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. F. Hoffmann-La Roche Ltd.
15.3.6.1. Company Overview
15.3.6.2. Delivery System Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. Pfizer, Inc.
15.3.7.1. Company Overview
15.3.7.2. Delivery System Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. Bayer AG
15.3.8.1. Company Overview
15.3.8.2. Delivery System Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Johnson & Johnson Services, Inc.
15.3.9.1. Company Overview
15.3.9.2. Delivery System Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Becton, Dickinson and Company
15.3.10.1. Company Overview
15.3.10.2. Delivery System Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. AstraZeneca plc
15.3.11.1. Company Overview
15.3.11.2. Delivery System Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Baxter International, Inc.
15.3.12.1. Company Overview
15.3.12.2. Delivery System Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview
15.3.13. Boston Scientific Corporation
15.3.13.1. Company Overview
15.3.13.2. Delivery System Portfolio
15.3.13.3. SWOT Analysis
15.3.13.4. Financial Overview
15.3.13.5. Strategic Overview
15.3.14. GenVivo, Inc.
15.3.14.1. Company Overview
15.3.14.2. Delivery System Portfolio
15.3.14.3. SWOT Analysis
15.3.14.4. Financial Overview
15.3.14.5. Strategic Overview